The trademark application GlyMab was filed by Scancell Limited, a corporation established under the laws of the United Kingdom of Great Britain and Northern Ireland (the "Applicant"). The application was published for oppositions on February 24, 2022, and it was registered by office on June 3, 2022 without any oppositions.
The application was filed in English (French was selected as the second language).